Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.
Smaletz O, Diz MD, do Carmo CC, Sabbaga J, Cunha-Junior GF, Azevedo SJ, Maluf FC, Barrios CH, Costa RL, Fontana AG, Madrigal V, Wainstein AJ, Yeda FP, Alves VA, Moro AM, Blasbalg R, Scott AM, Hoffman EW. Smaletz O, et al. Among authors: moro am. Gynecol Oncol. 2015 Aug;138(2):272-7. doi: 10.1016/j.ygyno.2015.05.023. Epub 2015 May 27. Gynecol Oncol. 2015. PMID: 26026738 Clinical Trial.
Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.
Lopes dos Santos M, Yeda FP, Tsuruta LR, Horta BB, Pimenta AA Jr, Degaki TL, Soares IC, Tuma MC, Okamoto OK, Alves VA, Old LJ, Ritter G, Moro AM. Lopes dos Santos M, et al. Among authors: moro am. PLoS One. 2013 Jul 31;8(7):e70332. doi: 10.1371/journal.pone.0070332. Print 2013. PLoS One. 2013. PMID: 23936189 Free PMC article.
Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission.
Smaletz O, Ismael G, Del Pilar Estevez-Diz M, Nascimento ILO, de Morais ALG, Cunha-Junior GF, Azevedo SJ, Alves VA, Moro AM, Yeda FP, Dos Santos ML, Majumder I, Hoffman EW. Smaletz O, et al. Among authors: moro am. Int J Gynecol Cancer. 2021 Apr;31(4):562-568. doi: 10.1136/ijgc-2020-002239. Epub 2021 Mar 4. Int J Gynecol Cancer. 2021. PMID: 33664128 Clinical Trial.
Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
Lindegren S, Andrade LN, Bäck T, Machado CM, Horta BB, Buchpiguel C, Moro AM, Okamoto OK, Jacobsson L, Cederkrantz E, Washiyama K, Aneheim E, Palm S, Jensen H, Tuma MC, Chammas R, Hultborn R, Albertsson P. Lindegren S, et al. Among authors: moro am. PLoS One. 2015 May 13;10(5):e0126298. doi: 10.1371/journal.pone.0126298. eCollection 2015. PLoS One. 2015. PMID: 25970341 Free PMC article.
Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings.
de Aguiar RB, Parise CB, Souza CR, Braggion C, Quintilio W, Moro AM, Navarro Marques FL, Buchpiguel CA, Chammas R, de Moraes JZ. de Aguiar RB, et al. Among authors: moro am. Cancer Lett. 2016 Feb 28;371(2):151-60. doi: 10.1016/j.canlet.2015.11.030. Epub 2015 Dec 3. Cancer Lett. 2016. PMID: 26655277 Free article.
Anti-digoxin Fab variants generated by phage display.
Murata VM, Schmidt MC, Kalil J, Tsuruta LR, Moro AM. Murata VM, et al. Among authors: moro am. Mol Biotechnol. 2013 Jun;54(2):269-77. doi: 10.1007/s12033-012-9564-1. Mol Biotechnol. 2013. PMID: 23359127
82 results